Company profile: Tetra Bio-Pharma
1.1 - Company Overview
Company description
- Provider of cannabinoid-derived drug development for inflammation, pain, ophthalmology, and oncology, including treatments targeting sepsis, acute respiratory distress syndrome, cytokine release syndrome, breakthrough and uncontrolled cancer pain, uveitis, proliferative vitreoretinopathy, chemotherapy-induced nausea and vomiting, cancer cachexia, and hepatocellular carcinoma.
Products and services
- Pain Management: Creates cannabinoid-based treatments for breakthrough and uncontrolled cancer pain, focusing on therapeutic interventions tailored to oncologic pain indications
- Inflammation Treatments: Develops cannabinoid-based therapies addressing sepsis, acute respiratory distress syndrome, and cytokine release syndrome, targeting inflammation-related conditions with indication-driven drug candidates
- Cannabinoid-Derived Drug Development: Engineers cannabinoid-derived therapeutics spanning inflammation, pain, ophthalmology, and oncology, architecting drug products aligned to these specific therapeutic areas and patient applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tetra Bio-Pharma
MDoloris
HQ: France
Website
- Description: Provider of medical equipment and monitoring solutions to soothe, lessen, monitor and assess patients' pain and its impact, including ANI Monitor V2, ANI MOC-9 and HFVI MOC-9 modules for Masimo Root to measure autonomic nervous system responses, NIPETM for neonatal parasympathetic evaluation in NICU settings, and a Web academy on ANI technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDoloris company profile →
Dogwood Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage antiviral therapies targeting fibromyalgia and Long COVID, including IMC-1, a fixed-dose combination of famciclovir and celecoxib designed to suppress herpes virus replication and reduce fibromyalgia symptoms, and IMC-2, a combination of valacyclovir and celecoxib developed to manage Long COVID-related fatigue, sleep issues, and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dogwood Therapeutics company profile →
Electromedical Technologies
HQ: United States
Website
- Description: Provider of pain relief to improve global wellness by relieving chronic and acute pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Electromedical Technologies company profile →
Regenesis
HQ: United States
Website
- Description: Provider of medical equipment focused on non-drug pain relief solutions, manufacturing devices designed to alleviate pain without pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regenesis company profile →
Thor Photomedicine
HQ: United Kingdom
Website
- Description: Provider of photobiomodulation (PBM) therapy using laser or LED light to improve tissue repair, reduce inflammation and relieve pain. Offers FDA- and CE-cleared THOR LX2.3 for oral mucositis, tendinopathies, and joint, neck and back pain, NovoTHOR whole-body PBM, and training for clinicians. Serves pioneering clinics and hospitals in 70 countries; the only LLLT company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Thor Photomedicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tetra Bio-Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tetra Bio-Pharma
2.2 - Growth funds investing in similar companies to Tetra Bio-Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tetra Bio-Pharma
4.2 - Public trading comparable groups for Tetra Bio-Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →